期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 960, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ejphar.2023.176166
关键词
Canagliflozin; Ulcerative colitis; In-silico; TLR4/MAPK/NF-kappa B; Nrf2/PPAR-gamma/SIRT1
This study demonstrates that canagliflozin can effectively attenuate ulcerative colitis by regulating multiple pathways and targets, reducing inflammation, alleviating oxidative stress, and restoring colonic function.
Ulcerative colitis (UC) is one of the most common subtypes of inflammatory bowel disease (IBD) that affects the colon and is characterized by severe intestinal inflammation. Canagliflozin is a widely used antihyperglycemic agent, a sodium-glucose cotransporter-2 (SGLT2) inhibitor that enhances urinary glucose excretion. This study aims to provide insights into the potential benefits of canagliflozin as a treatment for UC by addressing possible cellular signals. Acetic acid (AA; 4% v/v) was administered intrarectally to induce colitis. Canagliflozin is given orally at a dose of 10 mg/kg/day. Canagliflozin attenuates inflammation in AA-induced colitis, evidenced by significant and dose-dependently downregulation of p38 MAPK, NF-kappa B-p65, IKK, IRF3, and NADPH-oxidase as well as colonic levels of IL-6 and IL-1 beta and MPO enzymatic activity. Canagliflozin mitigates colonic oxidative stress by decreasing MDA content and restoring SOD enzymatic activities and GSH levels mediated by co-activating of Nrf2, PPAR gamma, and SIRT1 pathways. Moreover, an in-silico study confirmed that canagliflozin was specific to all target proteins in this study. Canagliflozin's binding affinity with its target proteins indicates and confirms its effectiveness in regulating these pathways. Also, network pharmacology analysis supported that canagliflozin potently attenuates UC via a multi-target and multi-pathway approach.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据